Outcome measures in asthma

N C Barnes
Department of Respiratory Medicine, The London Chest Hospital, London E2 9JX, UK

Introductory articles

Exacerbations of asthma: a descriptive study of 425 exacerbations

A E Tattersfield, D S Postma, P J Barnes, K Svensson, C–A Bauer, P M O'Byrne, C-G Lofdahl, R A Pauwels, A Ullman on behalf of the FACET International Study Group

The identification, prevention, and prompt treatment of exacerbations are major objectives of asthma management. We looked at change in PEF, symptoms, and use of rescue \( \beta \) agonists during the 425 severe exacerbations that occurred during a 12-month parallel group study (FACET) in which low and high doses of budesonide with and without formoterol were compared in patients with asthma. Oral corticosteroids were prescribed for severe exacerbations, the main study end point, defined as the need for a course of oral corticosteroids \((n = 311)\) or a reduction in morning PEF of \( >30\% \) on two consecutive days, PEF, symptoms, and bronchodilator use over the 14 days before and after the exacerbation were obtained from diary cards. Exacerbations were characterized by a gradual fall in PEF over several days, followed by more rapid changes over 2–3 days: an increase in symptoms and rescue \( \beta \) agonist use occurred in parallel, and both the severity and time course of the changes were similar in all treatment groups. Exacerbations identified by the need for oral corticosteroids were associated with more symptoms and smaller changes in PEF than those identified on the basis of PEF criteria. Female sex was the main patient characteristic associated with an increased risk of having a severe exacerbation. Exacerbations may be characterized predominantly by change in symptoms or change in PEF, but the pattern was not affected by the dose of inhaled corticosteroid or by whether the patient was taking formoterol. (Am J Respir Crit Care Med 1999;160:594–9)

Differences between asthma exacerbations and poor asthma control

H Reddel, S Ware, G Marks, C Salome, C Jenkins, A Woolcock

Background. Increased variation in peak expiratory flow (PEF) is characteristic of poorly controlled asthma and measurement of diurnal variability of PEF has been recommended for assessment of asthma severity, including during exacerbations. We aimed to test whether asthma exacerbations had the same PEF characteristics as poor asthma control. Methods. Electronic PEF records from 43 patients with initially poorly controlled asthma were examined for all exacerbations that occurred after PEF reached a plateau with inhaled corticosteroid treatment. Diurnal variability of PEF was compared during exacerbations, run–in (poor asthma control), and the period of stable asthma before each exacerbation. Findings. Diurnal variability was 21.3% during poor asthma control and improved to 5.3% (stable asthma) with inhaled corticosteroid treatment. 40 exacerbations occurred in 26 patients over 2–16 months; 38 (95%) of exacerbations were associated with symptoms of clinical respiratory infection. During exacerbations, consecutive PEF values fell linearly over several days then improved linearly. However, diurnal variability during exacerbations (7.7%) was not significantly higher than during stable asthma (5.4%, \( p = 0.1 \)). PEF data were consistent with impaired response to inhaled \( \beta_2 \) agonist during exacerbations but not during poorly controlled asthma. Interpretation. Asthmatics remain vulnerable to exacerbations during clinical respiratory infections, even after asthma is brought under control. Calculation of diurnal variability may fail to detect important changes in lung function. PEF variation is strikingly different during exacerbations compared with poor asthma control, suggesting differences in \( \beta_2 \) adrenoceptor function between these conditions. (Lancet 1999;353:364–9)
While health care professionals and patients may be able to recognise an exacerbation, defining what an exacerbation is for the purpose of clinical trials is not easy. Individual patients and physicians may have a different propensity threshold for determining that a worsening of asthma is an exacerbation rather than what they consider is the normal inherent variability in the condition. Furthermore, an individual’s readiness to report an exacerbation may vary over time because of changes in perception of symptoms related to changes in anxiety, depression or stress.

If a clinical outcome cannot be defined and measured it is difficult to determine reliably what effect drugs may have on this and to come to rational therapeutic choices. The situation is further confused by recent evidence that cherished notions of the interrelationship between, for instance, peak flow variability and exacerbations of asthma may not in fact be correct.

### What are asthma exacerbations?

At present there is no universally accepted definition of an asthma exacerbation. Expert reports on asthma outcomes have not addressed the issue directly or have only provided guidance.

An exacerbation could be described as a worsening of asthma that exceeds the normal day to day variability of lung function and symptoms and triggers, or should trigger, the need for increased treatment with more than just inhaled β₂ agonists. Measuring the number of exacerbations has become an important outcome measure in clinical trials. One of the first and the largest trials to measure asthma exacerbations prospectively was the FACET study. This 12 month long parallel group design study investigated four different treatment strategies: beclomethasone 100 µg twice daily, budesonide 100 µg twice daily plus formoterol 12 µg twice daily, budesonide 400 µg twice daily, and budesonide 400 µg twice daily plus formoterol 12 µg twice daily. The primary outcome variable in the study was severe exacerbations. The definition of a severe exacerbation was either required for a course of oral corticosteroids as judged by the clinical investigator or an episode in which morning peak expiratory flow (PEF) fell by more than 30% on two consecutive days from the mean morning PEF during the 10 days of the run in period. 852 patients entered the randomisation phase of the study and 694 completed the one year long study. In this time there were 425 severe exacerbations. Patients kept daily diary cards in which they measured morning and evening PEF and scored their symptoms and use of rescue medication; the study thus provided a unique opportunity to investigate exacerbations and their relation to PEF and symptoms. The first interesting result from the further analysis study is that 70% of the exacerbations were defined by a requirement for a course of oral corticosteroids rather than by a 30% decrease in PEF. This means that, despite clinicians having available to them carefully measured PEF, they chose to treat the patient for an exacerbation when the PEF had not fallen by 30%. This is even more revealing when the maximum decrease in PEF is compared in those whose exacerbation was defined by oral steroid use and those defined by a fall in PEF. In those defined as showing an exacerbation by a fall in PEF, decrease in peak flow was approximately twice as large as those defined by symptoms. The clue to the reason for this discrepancy probably lies in examination of the asthma symptoms score. Despite having a smaller decrement in PEF, the group defined by their requirement for oral cortico-

### Table 1: Aims of asthma management: GINA guidelines 1999

- Prevent troublesome symptoms night and day
- Prevent serious attacks
- Require little or no quick relief medication
- Have productive, physically active lives
- Have (near) normal lung function
- Prevent troublesome symptoms night and day
- Prevent serious attacks
- Require little or no quick relief medication
- Have productive, physically active lives
- Have (near) normal lung function
- Minimal (ideally no) need for as needed β₂ agonists
- No limitations on activities, including exercise
- Peak expiratory flow (PEF) diurnal variation of less than 20%
- (Near) normal PEF
- Minimal (or no) adverse effects from medicine

### Table 2: Aims of asthma management: GINA guidelines 1999

- Prevent troublesome symptoms night and day
- Prevent serious attacks
- Require little or no quick relief medication
- Have productive, physically active lives
- Have (near) normal lung function
- Prevent troublesome symptoms night and day
- Prevent serious attacks
- Require little or no quick relief medication
- Have productive, physically active lives
- Have (near) normal lung function
- Minimal (ideally no) need for as needed β₂ agonists
- No limitations on activities, including exercise
- Peak expiratory flow (PEF) diurnal variation of less than 20%
- (Near) normal PEF
- Minimal (or no) adverse effects from medicine

### Table 3: Aims of asthma management: BTS guidelines 1999

- To recognise asthma
- To abolish symptoms
- To restore normal or best possible long term airway function
- To reduce the risk of severe attack
- To enable normal growth to occur in children
- To minimise absence from school or work

One of the strengths of asthma guidelines is that they set out the aims of asthma management. These aims help clinicians, but are also increasingly influential in shaping the design of clinical trials by determining outcome measures. Current asthma guidelines emphasise the need for long term control of asthma. Asthma control is not defined by a single measurement such as normal respiratory function but by a whole series of parameters. The 1993 Global Initiative for Asthma (GINA) guidelines described seven efficacy aims plus emphasising the need for drug safety (table 1). These aims of asthma management can be broadly grouped into three areas: prevention of symptoms including exercise induced symptoms and minimal requirement for symptomatic relief with a short acting β₂ agonist; normalisation of lung function; and prevention of asthma exacerbations. The most recent version of the GINA guidelines has simplified these aims (table 2). The British Thoracic Society (BTS) guidelines also list the aims of asthma management (table 3). To achieve these aims of asthma management the guidelines propose treatment often using a combination of different drugs. The guidelines add that this should be achieved with medications which have as few side effects as possible. Clinicians have to choose the drug or drugs they believe will achieve the aims of asthma management and asthma control. It is, however, becoming increasingly apparent that the choice of which drug or drugs to use is not as easy as it might outwardly appear and that the interrelationship between the different facets of asthma control such as symptoms, pulmonary function, and exacerbations is complex.

Prevention of asthma exacerbations is a very important aim of asthma management as exacerbations are disruptive for patients and costly to treat. However,
steroids had a greater increase in symptoms than those
defined by a 30% fall in PEF. Is this because these
patients had a greater propensity for reporting symptoms
when their lung function declined or was it something
about the cause of the exacerbation which led to a
relative excess in symptoms? It might be possible to
shed some light on this from examining the records of
those patients who had more than one exacerbation to
see if different exacerbations had a common pattern or
not. The importance of symptoms in determining the
patient’s and doctor’s response to a worsening of asthma is
further reinforced by another analysis performed in the
paper. Despite being clearly instructed to contact the
trialist if there was a 30% decrease in their PEF, 76
patients neither contacted the trialist nor had a course
of steroids and yet their asthma recovered – if anything,
more rapidly than those who took the oral cortico-
steroids. Again there was a difference in the symptom
scores when this group and those who took oral steroids
were compared. Those patients who took a course of
oral steroids had a greater increase in symptoms than
those who did not. This again indicates that symptoms
were a very important factor in deciding on a pre-
scription for oral steroids. Concern has been expressed
that certain drugs, in particular long acting β2 agonists,
may blunt the patient’s ability to perceive an asthma
exacerbation. However, there was no difference in the
pattern of asthma exacerbations in the four limbs of the
study with no evidence that the prescription of long
acting β2 agonists blunted perception. The change in
symptoms and PEF seemed to go in parallel, so there
was little that patients could do to predict that they
were about to have an exacerbation and act to prevent
it.

Relation between exacerbations and peak
expiratory flow variability

Analysis of the FACTET study exacerbation data indicates
that the relation between changes in pulmonary function
and exacerbations is complex and either varies between
patients or in the same patient between ex-
acerbations. Further evidence of this is provided by the
paper by Reddel et al.1 In this study 43 patients were
followed for at least three months. At the beginning of
the study the authors say that the patients had poorly
controlled asthma based on their symptom frequency,
night time awakening, and bronchodilator use. It does
seem reasonable to state that these patients had poorly
controlled asthma. They had asthma symptoms on a
mean of 5.1 days per week, they were waking on 2.4
nights per week with asthma, and their mean morning
PEF was only 63.5% of predicted. There was a marked
improvement when patients were treated with inhaled
corticosteroids with asthma symptoms decreasing to 1.2
days per week, night time waking to only 0.1 nights
per week, and mean morning PEF improving to 90.2% of
predicted. An asthma exacerbation was defined as a fall in
PEF for at least two days of at least two standard
deviations below the mean morning pre-bronchodilator
PEF for the previous four weeks; the end of an ex-
acerbation was defined as recovery of the PEF to above
this level for at least two days.

Forty three per cent of patients had an exacerbation
of their asthma. The authors do not report whether
there were patients who had a course of oral steroids
but did not meet these pulmonary function criteria. The
pattern of change in PEF did not seem significantly
different from the FACTET study analysis. The key
finding of Reddel et al was that, although PEF worsened,
there was no increase in the diurnal variation in PEF
which was in marked contrast to the run in period of
the study. During the run in period when patients had
unstable asthma they had marked diurnal variation in
PEF. The authors suggest that, whereas marked diurnal
variability is a feature of poor asthma control, when an
exacerbation occurs PEF variability is not a feature.
They state that the asthma exacerbations were largely
due to viral infections, but the evidence for this is not
compelling. The evidence they give for viral aetiology
of exacerbations is that there were typical symptoms of
a viral upper respiratory tract infection yet viral isolation
was not performed. They claim that exacerbations were
unlikely to be caused by allergen exposure as asthma in
South Wales is perennial rather than seasonal because
of the high year round levels of house dust mite, but
this ignores the possibility that other allergens may have
caused the exacerbations and that other factors such as
air pollution or a combination of air pollution and
allergen exposure may have led to the exacerbation.
The authors suggest that the lack of diurnal variation
is due to downregulation of β2 receptor function caused
by the viral infection. However, it is also possible that
lack of diurnal variation is a feature of any exacerbation
of whatever cause when there is an increase in airway
inflammation. Another possible explanation for the
difference between the baseline period of poor asthma
control and the exacerbation of asthma is that the use
of inhaled corticosteroids modified the diurnal variation.
During the baseline period only 12 of the 26 patients
who experienced at least one exacerbation had been
taking inhaled steroids for three months or more. Patients
were then started on regular treatment with the
inhaled budesonide, although the dose of budesonide
during the treatment stage is not reported. However,
all patients were treated with inhaled steroids and pre-
sumably those who were on inhaled steroids during the
run in phase had the inhaled steroid dose increased. It
is known that inhaled steroids reduce diurnal variability
in PEF. It is therefore possible that, in the absence of
inhaled corticosteroids, an asthma exacerbation may
cause increased PEF but, in the presence of adequate
doses of inhaled steroids, although there is a fall in
peak flow, diurnal variability does not increase. This
interpretation is supported by a study in patients with
mild asthma in whom exacerbations of asthma were
induced by inoculation with rhinovirus and lung function
was monitored with home spirometry and an increase
in diurnal variation occurred.

These findings should give pause for thought and
stimulate further research. They indicate that the
relationship between different asthma outcome measures
is not simple and that these relationships are different
in different patients or vary in the same patient across
time. They show that apparently simple clinical concepts
such as what constitutes an asthma exacerbation or the
variability in peak flow in relation to episodes of poor
asthma control are complex and ill understood. This
has implications for clinical practice, research, and un-
derstandings of basic mechanisms.

Implications for clinical practice

The guidelines for asthma treatment clearly state that
asthma control can only be defined by looking at a
number of parameters (tables 1, 2 and 3). The guidelines
also indicate that in most patients a combination of
drugs is needed to control asthma – for example, inhaled
corticosteroids plus short acting β2 agonists at step 2 of
the BTS or GINA guidelines and inhaled corticosteroids

Outcome measures in asthma

and long acting bronchodilators or leukotriene receptor antagonists or theophyllines plus short acting β₂ agonists at step 3. Although they recognise the need for multiple drug therapy for many patients with asthma, they do not begin to help the practitioner in choosing between these different options nor do they articulate the fact that different drug therapies may have different relative strengths and weaknesses when it comes to different outcome measures. For instance, it is clear from the FACET study and other studies that, once a patient with asthma is taking inhaled corticosteroids at 400 μg/day or above, the mean improvement in pulmonary function gained by increasing inhaled corticosteroid dose is small. However, there may be a significant improvement in terms of prevention of asthma exacerbations when inhaled steroid doses are increased.

Addition of a long acting β₂ agonist leads to a more marked improvement in pulmonary function and symptoms and a lesser reduction in asthma exacerbations.

Addition of a leukotriene receptor antagonist seems both to improve pulmonary function and reduce asthma exacerbations, although the magnitude of this effect compared with other treatments is not yet established.

Theophyllines would appear at present to produce a modest improvement in lung function with, as yet, no evidence of any alteration in asthma exacerbation rate. The diverse way in which these different treatments, when added to low dose inhaled exacerbation prevention inhalers, affect asthma outcomes produces difficulties for clinical decision making. It is relatively easy to determine that a drug has improved pulmonary function or decreased symptoms within a short period of time but it is much more difficult to determine that a drug has reduced by 50% the risk of an asthma exacerbation when a patient may only have one or two asthma exacerbations per year. It is also important to recognise that most clinical trials – and therefore the recommendations of guidelines on which they are based – look at mean results when comparing treatments. It is evident, however, from the FACET study that not all patients experience asthma exacerbations in the same way. Furthermore, as the variability in response to different drugs within clinical trials becomes apparent, it is evident that all patients need to be treated individually when deciding on treatment options and that no one drug or combination of drugs will be suitable for all patients.

Implications for clinical research

The trend in recent years to evaluate a number of different outcome measures in clinical trials needs to continue as the true clinical profile of an anti-asthma drug can only be determined by evaluating several different outcome measures. This has implications for the type of clinical trial which needs to be performed; short term clinical trials with relatively limited numbers of patients may be sufficient to determine efficacy using pulmonary function but are unlikely to be of use when measuring asthma exacerbations where longer trials with larger numbers of patients are needed. The desire to evaluate a range of outcome measures may also have implications for the power calculations traditionally done before the start of a trial. These power calculations are usually performed with reference to the primary outcome measure, usually pulmonary function. However, if other outcome measures – particularly asthma exacerbations – are to be measured, then power calculations may have to be performed for each of the important outcome measures in the trial and the number of patients chosen so that all of these outcome measures can be evaluated in a statistically robust fashion. Further research needs to be performed to determine the interaction between different outcome measures. This may eventually enable clinicians to look at some combination of pulmonary function, symptoms, and rescue medication use which indicates a degree of clinical stability that makes an asthma exacerbation less likely. It is clear that pulmonary function alone cannot correlate strongly with the risk of asthma exacerbations as, in the FACET study, the group on low dose budesonide plus formoterol had better lung function than the group on high dose budesonide alone but a greater risk of asthma exacerbation.

It is evident from the analysis of exacerbations in the FACET study that not all patients behave in the same manner, or at different times the same patient may have a different pattern of response. This needs to be recognised when interpreting and presenting the results of clinical trials, with a move away from simply presenting mean data towards showing the mean data and the individual patient responses. The paper by Reddel et al shows that outcome measures do not have the same meaning when a patient is improving as when they are deteriorating. In this study the improvement in diurnal variation on increase in treatment was a sensitive measure of change. However, increased diurnal variation was not a feature of deteriorating asthma and would therefore not have been a sensitive measure for worsening of the disease. Furthermore, a decrease in usage of rescue β₂ agonist of four puffs/day when asthma improves may not mean the same as an increase in use of four puffs/day when asthma has previously been well controlled.

Implications for basic research

It is easy to measure pulmonary function and symptoms but determining the risk of an asthma exacerbation is difficult. If a simple way could be found to establish that airway inflammation is fully controlled, then it could be possible to determine rationally the dose of anti-inflammatory treatment needed to minimise the risk of exacerbation. The possibility of this approach being successful is suggested by a study in which the measurement of bronchial hyperresponsiveness was added to conventional clinical monitoring of disease to determine treatment needed to improve disease control. However, for use in primary care the measure of bronchial hyperresponsiveness is impractical and some simpler measure is needed. Measurement of exhaled nitric oxide (NO) does not seem to be a suitable candidate and other exhaled measurements are now being investigated. Another challenge for basic research is to try to determine the differing genetic or phenotypic patterns which underlie variability and response to disease, and a recently reported study indicating a link between polymorphisms in the promoter region of the 5-lipoxygenase gene and response to a leukotriene synthesis inhibitor is of particular interest.

Conclusion

The quality of asthma management has benefited from a clear exposition of the aims of management in various asthma guidelines. It is clear, however, that the relationship between these aims of management such as improvement of pulmonary function, improvement in symptoms, and decrease in the risk of asthma exacerbations is complex and different drugs may have different impacts on these different aims of asthma management. In order to improve our understanding
The aims of asthma management set out in guidelines are increasingly being reflected in outcome measures used in clinical trials.

To assess some of these outcome measures, particularly asthma exacerbations, will require clinical trials which are longer in duration than has previously been the norm.

There is no universally agreed definition of asthma exacerbations for use in clinical trials.

The relation between different outcome measures in asthma is complex and at present ill understood.

The relation between different outcome measures may vary according to whether asthma is well or poorly controlled and varies between patients.

Despite the availability of carefully measured peak expiratory flow rate in clinical trials, physicians’ decision making is still, to a large extent, driven by symptomatology of the basic pathophysiology of asthma and how it relates to clinical symptoms and lung function, and to improve the stability of health care practitioners to make rational choices about anti-asthmatic drugs, further research is needed into the interrelationship between these different aims of management. The availability of large databases for long term clinical trials provides an excellent opportunity for this research.

Outcome measures in asthma

NC Barnes

Thorax 2000 55: S70-S74
doi: 10.1136/thorax.55.suppl_1.S70

Updated information and services can be found at:
http://thorax.bmj.com/content/55/suppl_1/S70.citation

These include:

References
This article cites 2 articles, 0 of which you can access for free at:
http://thorax.bmj.com/content/55/suppl_1/S70.citation#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/